Prescriptions for Ozempic soar

Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real-world study says

Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

The Washington Post · 21h

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Fox Business on MSN · 20h

Pfizer scraps twice-daily weight loss pill danuglipron after study shows ‘high rates’ of adverse side effects

Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.

CNBC on MSN · 8h

Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops

Pfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped obesity drugs. Pfizer's move to drop two obesity drug candidates in the last year demonstrates how difficult it is to develop an effective,

Reuters on MSN · 20h

UPDATE 4-Pfizer drops twice-daily version of obesity pill over side effects

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting,

MarketWatch on MSN · 22h

Pfizer’s stock falls 6% after halting trial of obesity drug due to side effects

Pfizer Inc.’s stock tumbled 6% Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects.

CNBC on MSN · 14h

Expectations for Pfizer have been low, says Mizuho's Jared Holz on weight-loss pill setback

Jared Holz, Mizuho, joins 'Fast Money' to talk Pfizer's weight-loss pill setback. Republicans Warn Lockdowns Coming as China Pneumonia Spreads ‘Leaning tower’ in Italy on ‘high alert’ for collapse NBC's Antonia Hylton,

Reuters on MSN · 1d

UPDATE 1-Pfizer drops plan to study twice-daily obesity pill in late-stage studies

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates of side effects such as nausea and vomiting.

MarketWatch on MSN · 1d

Pfizer’s stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation

MARKET PULSE Pfizer Inc.’s stock fell 4% premarket Friday, after the company said it’s not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adults with obesity and type 2 diabetes after high rates of adverse events in the Phase 2b trial.

Reuters1d

Maker of Wegovy, Ozempic showers money on U.S. obesity doctors

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...

3mon

Wegovy weight-loss drugmaker sees profits soar

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

Yahoo1mon

These 15 metro areas saw biggest jumps in Ozempic use. They might not be where you expect.

A diabetes medication in short supply for the last two years often was prescribed to people who didn't have the disease, and prescribing rates varied dramatically across the country, new data shows.

The Motley Fool29d

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's. Both stocks could be winners for ...

Healthline17d

Black People Are Facing Greater Challenges Accessing Anti-Obesity Drugs Like Ozempic and Wegovy

Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...

Futurism2mon

Snack Food CEO Vows to Battle Ozempic

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Benefits Pro3d

Grappling with weight loss drug coverage? Options to help employers control costs

Instead of jumping to GLP-1 drugs that can be costly, a step therapy approach guides patients by offering individualized care ...

Medindia16d

Medications and their Potential to Cause Increase 'Throat sore'

This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending on Bing